- Conditions
- Bladder Cancer
- Interventions
- Nivolumab, Gemcitabine, Cisplatin
- Drug
- Lead sponsor
- Matthew Galsky
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 7
- States / cities
- Duarte, California • Los Angeles, California • New York, New York + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 127
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Non-muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma
- Interventions
- Durvalumab, Monalizumab
- Drug
- Lead sponsor
- John Sfakianos
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 5
- States / cities
- San Francisco, California • Tampa, Florida • New Brunswick, New Jersey + 1 more
- Conditions
- Urothelial Carcinoma, Bladder Cancer
- Interventions
- Pembrolizumab, Gemcitabine, Cisplatin, Consolidative Surgery
- Drug · Procedure
- Lead sponsor
- Jason R. Brown
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 9
- States / cities
- Indianapolis, Indiana • St Louis, Missouri • Albuquerque, New Mexico + 3 more
- Conditions
- Transitional Cell Carcinoma, Bladder Carcinoma, Urothelial Carcinoma
- Interventions
- Everolimus, Paclitaxel
- Drug
- Lead sponsor
- Matthew Galsky
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Bloomington, Indiana + 7 more
- Conditions
- Uveal Melanoma
- Interventions
- PAC-1, Entrectinib
- Drug
- Lead sponsor
- Arkadiusz Z. Dudek, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Breast Cancer
- Interventions
- PTK787, Trastuzumab
- Drug
- Lead sponsor
- Hoosier Cancer Research Network
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 8
- States / cities
- Elkhart, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 5 more
- Conditions
- Ovarian Cancer
- Interventions
- Doxil (Pegylated Liposomal Doxorubicin), BIBF 1120
- Drug
- Lead sponsor
- Hoosier Cancer Research Network
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Madison, Wisconsin
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Cisplatin, Etoposide, Radiation, Docetaxel
- Drug · Radiation
- Lead sponsor
- Nasser Hanna, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 15
- States / cities
- Galesburg, Illinois • Elkhart, Indiana • Evansville, Indiana + 10 more
- Conditions
- Advanced Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma
- Interventions
- Zolbetuximab, mFOLFOX6, CAPOX
- Drug
- Lead sponsor
- Midhun Malla
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Melanoma
- Interventions
- Pembrolizumab, Interleukin-2
- Drug
- Lead sponsor
- Ralph Hauke
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Relapse Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Selinexor, Carfilzomib, Isatuximab, Isatuximab SC Wearable Injection System, Dexamethasone
- Drug · Device
- Lead sponsor
- Natalie Callander
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Urothelial Carcinoma
- Interventions
- Carboplatin, Gemcitabine, Atezolizumab, Docetaxel
- Drug
- Lead sponsor
- Nabil Adra
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Omaha, Nebraska • Albuquerque, New Mexico + 1 more
- Conditions
- Prostate Cancer, Bone Metastases, Prostate Neoplasms
- Interventions
- LHRH agonist/antagonist, Bicalutamide, Radium-223 dichloride
- Drug · Radiation
- Lead sponsor
- Ajjai Alva, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Peoria, Illinois • Indianapolis, Indiana + 8 more
- Conditions
- Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer
- Interventions
- Durvalumab, Paclitaxel, Carboplatin, Radiation, Surgical Resection
- Device · Drug · Radiation + 1 more
- Lead sponsor
- Greg Durm, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • New York, New York + 1 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Pemetrexed, Cetuximab
- Drug
- Lead sponsor
- Nasser Hanna, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 11
- States / cities
- Galesburg, Illinois • Bloomington, Indiana • Elkhart, Indiana + 8 more
- Conditions
- Mesothelioma, Malignant
- Interventions
- Nivolumab, Ramucirumab
- Drug
- Lead sponsor
- Arkadiusz Z. Dudek, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Baltimore, Maryland • Detroit, Michigan + 1 more
- Conditions
- Rectal Cancer
- Interventions
- Capecitabine, Irinotecan, EUS, Neoadjuvant Chemotherapy, Preoperative Radiation, Surgery, Adjuvant Chemotherapy
- Drug · Procedure
- Lead sponsor
- Gabi Chiorean, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 9
- States / cities
- Elkhart, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 5 more
- Conditions
- T-Cell Neoplasm, Lymphoproliferative Disorders
- Interventions
- Pacritinib
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 6
- States / cities
- Duarte, California • Tampa, Florida • Ann Arbor, Michigan + 3 more
- Conditions
- Urothelial Carcinoma
- Interventions
- Atezolizumab, Bevacizumab
- Drug
- Lead sponsor
- Arjun Balar, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Chicago, Illinois • Minneapolis, Minnesota + 4 more
- Conditions
- Bladder Cancer, Urothelial Carcinoma
- Interventions
- OGX-427, Docetaxel
- Drug
- Lead sponsor
- Noah Hahn, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Duarte, California • Lancaster, California + 27 more
- Conditions
- Small Bowel Adenocarcinoma
- Interventions
- Nanoliposomal irinotecan, Oxaliplatin, 5 fluorouracil, Leucovorin
- Drug
- Lead sponsor
- Tiago Biachi de Castria
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 7
- States / cities
- Tampa, Florida • Chicago, Illinois • Fort Wayne, Indiana + 4 more
- Conditions
- Prostate Cancer, Metastatic Castrate-Resistant Prostate Cancer, PSA
- Interventions
- OGX-427, Abiraterone Acetate, Prednisone
- Drug
- Lead sponsor
- Costantine Albany
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 10
- States / cities
- Marina del Rey, California • Bloomington, Indiana • Goshen, Indiana + 6 more
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Azacitidine, Erythropoietin, Azacitidine (Monotherapy)
- Drug
- Lead sponsor
- Larry Cripe, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 9
- States / cities
- Galesburg, Illinois • Indianapolis, Indiana • Lafayette, Indiana + 4 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Cisplatin, Etoposide, Placebo, ZD6474
- Drug
- Lead sponsor
- Hoosier Cancer Research Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 19
- States / cities
- Newark, Delaware • Chicago, Illinois • Galesburg, Illinois + 13 more